Prednisone Dosing in Lupus Nephritis

Initial Dosing Strategy

The Kidney Disease: Improving Global Outcomes (KDIGO) 2024 guidelines recommend initiating prednisone at 0.5-0.6 mg/kg/day (maximum 40 mg/day) for Class III/IV lupus nephritis, with rapid tapering to ≤5 mg/day by 12 weeks 1, 2
For Class III/IV lupus nephritis, the reduced-dose scheme is preferred, with dosing as follows:
The American College of Rheumatology (ACR) 2012 guidelines recommended 1 mg/kg/day for Class IV with crescents, but this is now considered a less preferred, historical approach 3, 4

For Class V pure membranous lupus nephritis, start prednisone at 0.5 mg/kg/day combined with mycophenolate mofetil 2-3 g/day 3, 4

Administer methylprednisolone 0.25-0.5 g/day intravenously for up to 3 days as initial treatment before starting oral prednisone 1, 2

Always combine oral prednisone with immunosuppressive therapy (mycophenolate mofetil, cyclophosphamide, or calcineurin inhibitors) 1, 2
Taper aggressively to minimize toxicity, with a goal of reaching ≤5 mg/day by 12 weeks and <2.5 mg/day by 6 months 1, 2
Do not use the historical 1 mg/kg/day dosing unless dealing with severe crescentic disease or life-threatening extrarenal manifestations 3, 4
Do not continue high-dose prednisone beyond 2-4 weeks without aggressive tapering 1, 2
Do not omit intravenous methylprednisolone pulses when using reduced oral doses, as the combination strategy is what enables lower oral dosing while maintaining efficacy 1, 2

The American College of Rheumatology recommends combining prednisone with immunosuppressive therapy, such as mycophenolate mofetil 2-3 g/day or cyclophosphamide, from the outset 5, 6

The European League Against Rheumatism suggests a target maintenance dose of 5-7.5 mg/day during the first 3 years of immunosuppressive therapy 6

The American College of Rheumatology recommends assessing response at 6 months before making major treatment changes, and achieving partial response (≥50% reduction in proteinuria to subnephrotic levels) by 6 months, complete response by 12 months 6
If disease remains refractory despite appropriate tapering, the European League Against Rheumatism suggests switching immunosuppressive agents rather than increasing prednisone dose 6

The older American College of Rheumatology 2012 guidelines suggested tapering "over 6 to twelve months" to 10 mg/day, but this slower approach is associated with greater cumulative toxicity 5, 7
The American College of Rheumatology previously recommended a higher dose of 1 mg/kg/day for crescentic disease, but modern practice favors the reduced-dose scheme even with crescents 5, 8